Ebp1 activates podoplanin expression and contributes to oral tumorigenesis

Oncogene

Volumn 33, Issue 29, 2014, Pages 3839-3850

  Mei, Y ^a   Zhang, P ^b   Zuo, H ^a   Clark, D ^b   Xia, R ^b   Li, J ^b   Liu, Z ^c   Mao, L ^a,c  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

EBP1; oral; podoplanin; tumorigenesis

Indexed keywords

ERBB3 BINDING PROTEIN 1; PODOPLANIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION; WOUND HEALING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL COMMUNICATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MOUTH NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA-BINDING PROTEINS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84904638395     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.354     Document Type: Article

References (34)

1. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res 2008; 28: 2997-3006
2. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer 2007; 96: 1-5
3. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ.et al.. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006; 107: 563-569
4. Kreppel M, Kreppel B, Drebber U, Wedemayer I, Rothamel D, Zöller JE.et al.. Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications. Oral Dis 2012; 18: 692-699
5. Mashhadiabbas F, Mahjour F, Mahjour SB, Fereidooni F, Hosseini FS. The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 240-250
6. Shimamura Y, Abe T, Nakahira M, Yoda T, Murata S, Sugasawa M. Immunohistochemical analysis of oral dysplasia: diagnostic assessment by fascin and podoplanin expression. Acta Histochem Cytochem 2011; 44: 239-245
7. De Sousa SF, Gleber-Netto FO, De Oliveira-Neto HH, Batista AC, Nogueira Guimarães Abreu MH, De Aguiar MC. Lymphangiogenesis and podoplanin expression in oral squamous cell carcinoma and the associated lymph nodes. Appl Immunohistochem Mol Morphol 2012; 20: 588-594
8. Funayama A, Cheng J, Maruyama S, Yamazaki M, Kobayashi T, Syafriadi M.et al.. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas. Pathobiology 2011; 78: 171-180
9. Huber GF, Fritzsche FR, Züllig L, Storz M, Graf N, Haerle SK.et al.. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer 2011; 129: 1404-1409
10. Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y.et al.. Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol 2012; 33: 183-194
11. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L.et al.. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008; 26: 354-360
12. Darnell Jr JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2: 740-749
13. Neph S, Stergachis AB, Reynolds A, Sandstrom R, Borenstein E, Stamatoyannopoulos JA. Circuitry and dynamics of human transcription factor regulatory networks. Cell 2012; 150: 1274-1286
14. Kim CK, Nguyen TL, Joo KM, Nam DH, Park J, Lee KH.et al.. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res 2010; 70: 9730-9974
15. Hamburger AW. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J Mammary Gland Biol Neoplasia 2008; 13: 225-23
16. Lessor TJ, Yoo JY, Xia X, Woodford N, Hamburger AW. Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. J Cell Physiol 2000; 183: 321-329
17. Zhang Y, Akinmade D, Hamburger AW. The ErbB3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and AR-mediated transcription. Nucleic Acids Res 2005; 33: 6024-6033
18. Zhang Y, Ali TZ, Zhou H, DSouza DR, Lu Y, Jaffe J.et al.. ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. Cancer Res 2010; 70: 240-248
19. Scholl FG, Gamallo C, Quintanilla M. Ectopic expression of PA2.26 antigen in epidermal keratinocytes leads to destabilization of adherens junctions and malignant progression. Lab Invest 2000; 80: 1749-1759
20. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplaninmediated remodeling of the actin cytoskeleton. Cancer Cell 2006; 9: 261-272
21. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, Molina JR.et al.. miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 2010; 49: 981-990
22. Hwang YS, Xianglan Z, Park KK, Chung WY. Functional invadopodia formation through stabilization of the PDPN transcript by IMP-3 and cancer-stromal crosstalk for PDPN expression. Carcinogenesis 2012; 33: 2135-2146
23. Hantusch B, Kalt R, Krieger S, Puri C, Kerjaschki D. Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol Biol 2007; 8: 20
24. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010; 140: 460-476
25. Martín-Villar E, Yurrita MM, Fernández-Muñoz B, Quintanilla M, Renart J. Regulation of podoplanin/PA2.26 antigen expression in tumour cells. Involvement of calpain-mediated proteolysis. Int J Biochem Cell Biol 2009; 41: 1421-1429
26. Zhou X, Chen W, Zhang Y, Sun J, Wang Q, Yu Y. Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer. J Cancer Res Clin Oncol 2010; 136: 891-896
27. Peterziel H, Müller J, Danner A, Barbus S, Liu HK, Radlwimmer B.et al.. Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. Neuro Oncol 2012; 14: 426-439
28. Honma M, Minami-Hori M, Takahashi H, Iizuka H. Podoplanin expression in wound and hyperproliferative psoriatic epidermis: regulation by TGF-beta and STAT-3 activating cytokines, IFN-gamma, IL-6, and IL-22. J Dermatol Sci 2012; 65: 134-140
29. Shen Y, Chen CS, Ichikawa H, Goldberg GS. SRC induces podoplanin expression to promote cell migration. J Biol Chem 2010; 285: 9649-9656
30. Kunita A, Kashima TG, Ohazama A, Grigoriadis AE, Fukayama M. Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol 2011; 179: 1041-1049
31. Ohta M, Abe A, Ohno F, Hasegawa Y, Tanaka H, Maseki S.et al.. Positive and negative regulation of podoplanin expression by TGF-beta and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines. Oral Oncol 2012; 49: 20-26
32. Monie TP, Perrin AJ, Birtley JR, Sweeney TR, Karakasiliotis I, Chaudhry Y.et al.. Structural insights into the transcriptional and translational roles of Ebp1. EMBO J 2007; 26: 3936-3944
33. Mei YP, Liao JP, Shen J, Yu L, Liu BL, Liu L.et al.. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene 2012; 31: 2794-2804
34. Mei Y, Yuan Z, Song B, Li D, Ma C, Hu C.et al.. Activating transcription factor 3 up-regulated by c-Jun NH(2)-terminal kinase/c-Jun contributes to apoptosis induced by potassium deprivation in cerebellar granule neurons. Neuroscience 2008; 151: 771-779.